Market capitalization | $3.64m |
Enterprise Value | $3.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 31.67 |
P/S ratio (TTM) P/S ratio | 30.33 |
P/B ratio (TTM) P/B ratio | 8.39 |
Revenue growth (TTM) Revenue growth | -49.59% |
Revenue (TTM) Revenue | $120.00k |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
1 Analyst has issued a forecast Organovo Holdings, Inc.:
1 Analyst has issued a forecast Organovo Holdings, Inc.:
Dec '24 |
+/-
%
|
||
Revenue | 0.12 0.12 |
50%
50%
|
|
Gross Profit | -0.16 -0.16 |
433%
433%
|
|
EBITDA | -12 -12 |
37%
37%
|
EBIT (Operating Income) EBIT | -13 -13 |
36%
36%
|
Net Profit | -12 -12 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Keith Murphy |
Employees | 20 |
Founded | 2012 |
Website | www.organovo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.